KRAIG BIOCRAFT LABORATORIES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
KRAIG BIOCRAFT LABORATORIES, INC. (KBLB) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 500.00 thousand shares for the 12-month period ending 2025-12-31, per its POS AM filed 2026-05-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-05-11
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-12-31 was -6.00M shares.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-09-30 was 500.00K shares, a 91.74% decline year-over-year.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2024-12-31 was 0.00 shares.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2024-09-30 was 6.05M shares.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2024 was 16.70M shares, a 16.50% decline from fiscal 2023.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2023 was 20.00M shares, a 19.15% increase from fiscal 2022.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2022 was 16.79M shares, a 97.48% increase from fiscal 2021.
- KRAIG BIOCRAFT LABORATORIES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 8.50M shares, a 172.00% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|---|
| 2025-12-31 | -6.00M shares derived: POS AM 12 month − 10-Q 9 month · filed 2026-05-11 | -5.50M shares derived: sum of 2 quarters · filed 2026-05-11 | 500.00K shares POS AM · filed 2026-05-11 | |
| 2025-09-30 | 500.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 6.50M shares 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 6.00M shares 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 6.05M shares derived: sum of 2 quarters · filed 2025-03-28 | 16.70M shares 10-K · filed 2025-03-28 | |
| 2024-09-30 | 6.05M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 16.70M shares 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 10.65M shares 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | 20.00M shares 10-K · filed 2024-04-01 | |||
| 2022-12-31 | 5.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 5.69M shares derived: sum of 2 quarters · filed 2024-04-01 | 5.69M shares derived: sum of 3 quarters · filed 2024-04-01 | 16.79M shares 10-K · filed 2024-04-01 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 11.10M shares 10-Q · filed 2022-11-14 | 11.10M shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | 11.10M shares 10-Q · filed 2022-08-01 | 11.10M shares derived: sum of 3 quarters · filed 2023-03-29 | 11.60M shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | 11.10M shares 10-Q · filed 2022-05-06 | 11.10M shares derived: sum of 2 quarters · filed 2023-03-29 | 11.60M shares derived: sum of 3 quarters · filed 2023-03-29 | 11.60M shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 500.00K shares derived: sum of 2 quarters · filed 2023-03-29 | 500.00K shares derived: sum of 3 quarters · filed 2023-03-29 | 8.50M shares 10-K · filed 2023-03-29 |
| 2021-09-30 | 500.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | 500.00K shares derived: sum of 2 quarters · filed 2021-11-05 | 8.50M shares 10-Q · filed 2021-11-05 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 8.00M shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 8.00M shares 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | 3.13M shares 10-K · filed 2022-03-16 | |||
| 2019-12-31 | 30.70M shares 10-K · filed 2020-03-27 |